Summary of project PR001699
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001699. The data can be accessed directly via it's Project DOI: 10.21228/M83B08 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR001699 |
| Project DOI: | doi: 10.21228/M83B08 |
| Project Title: | Untargeted metabolomics revealed multiple metabolic perturbations in plasma of T2D patients in response to Liraglutide |
| Project Summary: | Despite the global efforts put into the clinical research and studies in order to protect against Type-2 diabetes mellitus (T2DM), the incidence of T2DM remains high causing a major health problem and impacting the health and care systems. Therefore, T2DM-related treatments and therapies are continuously invented for the clinical use, including Liraglutide. The last is a GLP-1 analogue and shows its beneficial health outcomes e.g., improved glycemic control, lower body weight, and reduced cardiovascular disease risks. The intrinsic mechanisms of these beneficial effects are not fully understood; however, our research group has previously published proteomics work demonstrating the involvement of certain important proteins in part in the beneficial health outcomes of Liraglutide. Since proteomics and metabolomics are complementary to each other in the context of the biological pathways, studying the metabolic impacts of Liraglutide on T2DM patients would add further information about the beneficial health outcomes of Liraglutide. Thus, herein, we performed an untargeted metabolomics approach for identifying metabolic pathways impacted by the treatment of Liraglutide in T2DM patients. Methods: Untargeted liquid chromatography coupled with mass spectrometry was used for metabolomics analysis of plasma samples collected from T2DM patients (n=20) before and after receiving Liraglutide treatment. Metabolic profiling and related pathway and network analyses were conducted. Results: The metabolic profiling analyses identified 93 endogenous metabolites were significantly affected by the Liraglutide treatments, which 49 metabolites up-regulated and 44 metabolites down-regulated. Moreover, the metabolic pathway analyses revealed that the most pronounced metabolite and metabolic pathways that were affected by the Liraglutide treatment was Pentose and glucuronate interconversion, suggesting the last may be a potential target of the Liraglutide treatment could be involved in part in the beneficial effects seen in T2DM patients, specially, we found that glucuronate interconversion pathway which is known by its role in eliminating toxic and undesirable substances from the human body, impacted in Liraglutide treated patients. The last findings ar consistence with our previous proteomics findings. Conclusion: These findings, taken together with our previous results, provide a deeper understanding of the underlying mechanisms involved in the beneficial effects of Liraglutide at the proteomic and metabolic levels in T2DM patients. |
| Institute: | King Faisal Specialist Hospital and Research Centre (KFSHRC) |
| Last Name: | Al Mogren |
| First Name: | Maha |
| Address: | Zahrawi Street, Al Maather, Riyadh 11211, Saudi Arabia |
| Email: | malmogren@alfaisal.edu |
| Phone: | 966541205332 |
Summary of all studies in project PR001699
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST002735 | Untargeted metabolomics revealed multiple metabolic perturbations in plasma of T2D patients in response to Liraglutide | Homo sapiens | King Faisal Specialist Hospital and Research Centre (KFSHRC) | MS* | 2023-07-02 | 1 | 40 | Uploaded data (73.3G)* |
| ST003056 (Available on 2024-08-01) | Untargeted metabolomics revealed multiple metabolic perturbations in plasma of T2D patients in response to Liraglutide - Part 2 | Homo sapiens | King Faisal Specialist Hospital and Research Centre (KFSHRC) | MS* | - | - | 46 | Not available |
